201 related articles for article (PubMed ID: 31826897)
1. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
[TBL] [Abstract][Full Text] [Related]
2. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
[TBL] [Abstract][Full Text] [Related]
3. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
4. Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan.
Satoh E; Sasaki Y; Ohkuma R; Takahashi T; Kubota Y; Ishida H; Hamada K; Kiuchi Y; Tsunoda T
Cancer Sci; 2018 Dec; 109(12):3896-3901. PubMed ID: 30315613
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Anticancer Drug Prices with Outcomes of Overall Survival and Progression-Free Survival in Clinical Trials in Japan.
Okabe A; Hayashi H; Maeda H
Curr Oncol; 2023 Feb; 30(2):1776-1783. PubMed ID: 36826098
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
7. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
Vogler S; Vitry A; Babar ZU
Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
[TBL] [Abstract][Full Text] [Related]
8. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
9. Drug Prices and Value of Oncology Drugs in Italy.
Russo P; Marcellusi A; Zanuzzi M; Carletto A; Fratto ME; Favato G; Staniscia T; Romano F
Value Health; 2021 Sep; 24(9):1273-1278. PubMed ID: 34452706
[TBL] [Abstract][Full Text] [Related]
10. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
[TBL] [Abstract][Full Text] [Related]
11. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
Herbrand AK; Schmitt AM; Briel M; Ewald H; Goldkuhle M; Diem S; Hoogkamer A; Joerger M; Moffa G; Novak U; Hemkens LG; Kasenda B
JAMA Netw Open; 2021 Mar; 4(3):e210380. PubMed ID: 33651108
[TBL] [Abstract][Full Text] [Related]
12. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
13. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
He Q; Li Q; Lv F; Kaitin KI; Shao L
Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
[TBL] [Abstract][Full Text] [Related]
14. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
[TBL] [Abstract][Full Text] [Related]
15. Simulated Medicare Drug Price Negotiation Under the Inflation Reduction Act of 2022.
Rome BN; Nagar S; Egilman AC; Wang J; Feldman WB; Kesselheim AS
JAMA Health Forum; 2023 Jan; 4(1):e225218. PubMed ID: 36705916
[TBL] [Abstract][Full Text] [Related]
16. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
[TBL] [Abstract][Full Text] [Related]
17. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
Michaeli DT; Michaeli T
Pharmacoeconomics; 2024 Jan; 42(1):117-131. PubMed ID: 37855850
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
19. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
[TBL] [Abstract][Full Text] [Related]
20. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
Luo X; Du X; Huang L; Guo Q; Tan R; Zhou Y; Li Z; Xue X; Li T; Le K; Qian F; Chow SC; Yang Y
Lancet Reg Health West Pac; 2023 Mar; 32():100670. PubMed ID: 36785854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
